United-Guardian Q2 net income rises 16% to $728,579 on 10% sales growth
United-Guardian reported second-quarter 2026 net sales of $3,108,267, up 10% from $2,838,225 a year earlier, and net income of $728,579 ($0.16 per share), up 16% from $626,826 ($0.14 per share). For the first half, net sales rose 12% to $5,980,489 and net income rose 30% to $1,547,481 ($0.34 per share), which included $339,493 of settlement income that the company did not report in the 2025 period.
Key points
- Q2 2026 cosmetic ingredient sales rose 44%, mainly from higher purchases by Ashland Specialty Ingredients, after its 2025 inventory levels were reduced.
- Q2 2026 pharmaceutical sales rose 1%; first-half pharmaceutical sales rose 11%, with Renacidin the primary driver.
- First-half 2026 settlement income was $339,493, compared with none in the first half of 2025.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.